Travere Therapeutics, Inc. SEC Filing
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Elizabeth Reed submitted a Form 144 indicating a proposed sale of $278,861.00 worth of Common stock via a stock option exercise for 10,000 shares on 03/16/2026. The filing also lists prior dispositions by Ms. Reed in the past three months: $278,317.00 for 10,000 shares on 02/17/2026, $96,360.09 for 2,994 shares on 02/04/2026, $230,463.88 for 7,175 shares on 02/03/2026, and $273,420.00 for 10,000 shares on 01/20/2026.
Insights
Form 144 lists a proposed issuer-side sale of 10,000 common shares by stock option exercise on 03/16/2026.
The filing records a planned stock option exercise for 10,000 shares with cash payment on 03/16/2026. It also enumerates prior dispositions by the same holder across January–February 2026 with the exact share and proceeds figures.
These entries are routine Rule 144 notices; cash‑flow treatment and any holding‑period or volume‑limit qualifiers are not stated in the excerpt. Subsequent SEC or broker confirmations would show whether the transactions were completed.
AI-generated analysis. How Rhea-AI works. Not financial advice.